ZYLM (Central Asia Lumeichun Biotechnology) Accounts Payable: $0.87 Mil (As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

What is Central Asia Lumeichun Biotechnology Accounts Payable?

Central Asia Lumeichun Biotechnology ZYLM Accounts Payable is $0.87 Mil as of Jun. 2026.

Central Asia Lumeichun Biotechnology's Accounts Payable for the quarter that ended in Jun. 2026 was $0.87 Mil.

Central Asia Lumeichun Biotechnology's quarterly Accounts Payable increased from Dec. 2025 ($0.26 Mil) to Mar. 2026 ($1.14 Mil) but then declined from Mar. 2026 ($1.14 Mil) to Jun. 2026 ($0.87 Mil).

Central Asia Lumeichun Biotechnology's annual Accounts Payable increased from Aug. 2023 ($0.01 Mil) to Dec. 2024 ($0.02 Mil) and increased from Dec. 2024 ($0.02 Mil) to Dec. 2025 ($0.26 Mil).

Central Asia Lumeichun Biotechnology Accounts Payable Related Terms

Central Asia Lumeichun Biotechnology Accounts Payable Historical Data

* Premium members only.

The historical data trend for Central Asia Lumeichun Biotechnology's Accounts Payable can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Central Asia Lumeichun Biotechnology Accounts Payable Chart

Central Asia Lumeichun Biotechnology Annual Data
Trend Mar07 Mar08 Mar09 Mar10 Mar11 Mar14 Mar15 Aug23 Dec24 Dec25
Accounts Payable
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.33 0.33 0.01 0.02 0.26

Central Asia Lumeichun Biotechnology Quarterly Data
Dec09 Mar10 Jun10 Sep10 Dec10 Mar11 Jun13 Jun15 Sep15 Dec15 Nov22 Feb23 May23 Aug23 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Accounts Payable Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.02 0.26 0.26 1.14 0.87

Central Asia Lumeichun Biotechnology Accounts Payable Calculation

Accounts Payable represents any money that a company owes its suppliers for goods and services purchased on credit and is expected to pay within the next year or operating cycle.

Frequently Asked Questions Learn more about Accounts Payable →
What does a Accounts Payable of $0.87 Mil mean?
Central Asia Lumeichun Biotechnology (ZYLM) has a Accounts Payable of $0.87 Mil as of Jun. 2026. Accounts Payable is any money that a company owes for goods and services purchased on credit and is expected to pay within the next year. View historical data on Central Asia Lumeichun Biotechnology and its competitors.
Is Central Asia Lumeichun Biotechnology's Accounts Payable too high?
Central Asia Lumeichun Biotechnology's current Accounts Payable is $0.87 Mil.
How does Central Asia Lumeichun Biotechnology's Accounts Payable compare to RHE and DVCR?
Central Asia Lumeichun Biotechnology's Accounts Payable of $0.87 Mil can be compared against companies in the Consumer Packaged Goods industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Accounts Payable for a Consumer Packaged Goods company?
A good Accounts Payable depends on the Consumer Packaged Goods industry context. However, Accounts Payable should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Accounts Payable mean?
A high Accounts Payable can signal that a stock is expensive relative to its fundamentals. Accounts Payable is any money that a company owes for goods and services purchased on credit and is expected to pay within the next year. View historical data on Central Asia Lumeichun Biotechnology and its competitors. Central Asia Lumeichun Biotechnology's current Accounts Payable is $0.87 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Central Asia Lumeichun Biotechnology stock overvalued right now?
Central Asia Lumeichun Biotechnology (ZYLM) has a current Accounts Payable of $0.87 Mil. The current Accounts Payable is $0.87 Mil. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Accounts Payable calculated?
Accounts Payable is calculated from a company's financial statements. For Central Asia Lumeichun Biotechnology (ZYLM), the current Accounts Payable is $0.87 Mil as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Central Asia Lumeichun Biotechnology Business Description

Address Longguan Avenue, Room 1401, Yunhua Building, Longhua District, Shenzhen, CHN
Central Asia Lumeichun Biotechnology Inc is an ecological agriculture company. It operates a sika deer breeding base in southern China.